Recent News

• 24 March 2026   Press Release

  Enamine Joins Agora Open Science Trust and Variational AI to Advance Open-Science Discovery of PRMT6 Inhibitors

  Enamine, a leading integrated drug discovery contract research organization (CRO) has today announced its participation in an open-science collaboration with Variational AI and the Agora Open Science Trust. This initiative aims to advance the discovery of novel small-molecule inhibitors targeting PRMT6, which is a therapeutic target implicated in Spinal and Bulbar Muscular Atrophy (SBMA), a rare neuromuscular disorder currently lacking approved treatments that slow or halt the progression of the disease.

• 25 February 2026   Press Release

  Chemspace Platform Enables Exploration of Chemical Space on a Trillion Scale

  Kyiv, Ukraine, 25 February 2026 – Chemspace, a global provider of chemical compounds and drug discovery services, today announced the integration of the xREAL Space by Enamine, a contract research organization and the world's largest supplier of screening compounds and building blocks, into the Chemspace platform, allowing researchers to search and purchase trillions of compounds through a single online source.

• 28 January 2026   Press Release

  Enamine and Chemspace Join IHI Project LIGAND-AI to Advance Artificial Intelligence (AI)-Driven Drug Discovery

  Frankfurt, Germany / Kyiv, Ukraine, 28 January 2026 – The new multi-sector public-private partnership funded by the Innovative Health Initiative (IHI) brings together 18 partners across nine countries to generate large open, high-quality datasets of protein–ligand interactions and use them to train artificial intelligence (AI) models capable of predicting candidate molecules as suitable binders for thousands of human proteins.